Presentation

BerGenBio is a biopharmaceutical company developing drugs that target AXL as a potential cornerstone therapy for cancer and severe respiratory infections. The company has two potentially first-in-class drugs: bemcentinib, a small molecule AXL inhibitor in several Phase II trials and tilvestamab, a selective anti-AXL-monoclonal antibody in a Phase Ib trial. In parallel, BerGenBio is developing companion diagnostic tests to identify patients most likely to benefit from its drugs.

Recent highlights
In November, BerGenBio received FDA’s Fast Track Designation for bemcentinib in combination with an anti-PD-L1 agent in STK11 altered advanced/metastatic NSCLC patients. In April, the company announced that the Phase II study of bemcentinib in combination with SoC therapy in hospitalised COVID-19 patients met its primary efficacy endpoint with no clinically relevant safety signals. Subsequently, bemcentinib will be studied in the EU-SolidAct trial in up to 500 hospitalized COVID-19 patients. In June, BerGenBio presented at ASCO the Phase I data of bemcentinib in combination with docetaxel in patients with previously treated advanced NSCLC, showing promising antitumor activity with 35% achieving a partial response and 47% attaining stable disease with a manageable safety profile.

Outlook
BenGenBio will focus on its lead molecule bemcentinib in two key indications, first-line NSCLC and COVID-19. The business strategy is built on data gathered from a broad clinical exploration, with both having strong evidence of bemcentinib activity, options for accelerated registration, compelling competitiveness, and high unmet medical needs.